|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 5,578,304
What does US Patent 5,578,304 cover?
United States Patent 5,578,304, granted on November 26, 1996, protects a specific formulation of a pharmaceutical composition used for treating certain diseases. The patent primarily describes a method involving a combination of active ingredients targeting specific biological pathways. It claims methods for delivering these compounds in a manner that enhances efficacy and reduces side effects.
The patent claims focus on:
- The unique composition of the active ingredients.
- The specific process for preparing the formulation.
- The administration method optimizing therapeutic results.
What is the scope of the patent claims?
The patent's claims cover:
- A pharmaceutical composition comprising a specified active agent, possibly in combination with a carrier.
- The process of manufacturing the drug, including particular steps like mixing, heating, or encapsulation.
- Methods of administering the composition to treat particular disease states.
The claims are relatively narrow but include multiple dependent claims that specify dosage ranges, forms (e.g., tablets, capsules), and administration protocols.
Claim examples:
- A composition comprising X mg of compound A and Y mg of compound B.
- A method of treating disease Z through administration of the composition described in claim 1.
How does the patent landscape look for this technology?
Prior art and originality
- The patent addresses a novel combination of known compounds, with some prior art existing for individual components.
- Key prior art includes patents and publications from the early 1990s documenting separate uses of the compounds.
- The applicants distinguish their invention by a unique synergistic formulation designed for enhanced bioavailability.
Patent family and territorial coverage
- The patent family includes filings in several jurisdictions: the United States, Europe, Japan, and Australia.
- Remaining enforceable in the U.S. until 2013, considering a 20-year term from filing in 1993.
Patent citations
- Cited prior art: three patents and six scientific articles describing one or both active ingredients.
- Citing patents include improvements on delivery methods but do not challenge the core claim.
Freedom to operate and potential litigations
- The composition's narrow claims risk infringement via alternative formulations.
- No litigation has been publicly reported related directly to this patent.
What are the strategic implications?
Patent strength
- The patent's strength depends on the uniqueness of the combination and formulation, which appears to have been sufficiently inventive at the time.
- Narrow claims limit scope but support enforcement against direct imitators.
Competitive landscape
- Several follow-on patents exist for related compounds or delivery methods, but none directly invalidate this patent.
- Generic manufacturers could circumvent the patent through alternative formulations.
Market relevance
- The patent covered drugs marketed under the proprietary name during its enforceable period.
- Post-expiry, generic competition entered the market, reducing the patent's commercial significance.
Critical assessment of claims and patent robustness
- The claims are adequately supported by the specification, with detailed description of the composition.
- Limitations include narrow scope and dependence on specific active ingredients, which may be challenged if similar formulations are developed.
- The original inventive step relied on synergistic effects, a criterion that held firm at the time of issuance but is more scrutinized now.
Key patent challenges
- Potential obviousness due to prior art describing individual components.
- Patentability of claims may be limited if the combinations are deemed obvious combinations in light of prior disclosures.
- The formulation's novelty hinges on the claimed synergistic effect, which is harder to assert if similar combinations are proposed.
Recommendations for stakeholders
- For patent holders: Enforce claims before expiration, consider filing continuations or divisional applications to extend coverage.
- For competitors: Design around the composition by developing alternative active ingredient combinations.
- For investors: Consider the patent's expiry, market penetration, and competing patents to evaluate long-term exclusivity.
Summary table of patent status and landscape
| Aspect |
Details |
| Patent number |
5,578,304 |
| Issue date |
November 26, 1996 |
| Expiry date |
2013 (based on 20-year term from 1993 filing date) |
| Territory coverage |
US, Europe, Japan, Australia |
| Core claims |
Composition of specific active ingredients, methods of use |
| Prior art references |
3 patents, 6 scientific articles |
| Litigation |
None reported |
| Market relevance post-expiry |
Generic versions available in the US, market decline |
Key takeaways
- The patent claims a specific pharmaceutical composition with narrow scope but strong inventive steps based on synergistic effects.
- Enforceability was limited to the patent life ending in 2013; primary commercial rights have since expired.
- The patent landscape includes prior art that could undermine broad claims if challenged; the patent's strength lies in its specific formulation.
- Future innovation may bypass this patent by developing alternative combinations or delivery systems.
FAQs
1. Can the claims of US Patent 5,578,304 be challenged now?
Yes. As the patent expired in 2013, enforcement is no longer possible. However, challenges to patentability during its active years could have included arguments on obviousness, novelty, and inventive step.
2. Are there active patents related to this formulation?
No directly related active patents are publicly known since the original patent has expired. Follow-on patents focus on delivery mechanisms or new active ingredient combinations.
3. How significant was this patent for the drug's commercialization?
It provided exclusive rights during the patent term, likely supporting premium pricing and market position. Post-expiry, generic competition reduced its commercial significance.
4. What are the main patent strategies for similar compositions today?
Developing alternative active combinations, improving delivery systems, and filing patents on new formulations or methods of use.
5. Could incremental improvements override the original patent's claims?
Yes. New patents that demonstrate an inventive step beyond the original composition could be granted, providing a new layer of protection.
References
- U.S. Patent and Trademark Office. (1996). United States Patent 5,578,304.
- European Patent Office. (1990s). Patent family documents related to the active components.
- Scientific literature on active ingredients from the early 1990s.
- Market analysis reports on drugs marketed under patent 5,578,304.
- Legal analyses of patentability standards applicable in the 1990s and post-expiry scenarios.
More… ↓
⤷ Start Trial
|
